NurExone BiologicFRA:J90 +4.09%36 FCF Yield % is -13.03 as of Jul. 01, 2026. GuruFocus rates FRA:J90 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, NurExone Biologic ranks worse than 56.75% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
NurExone Biologic FCF Yield % Related Terms
NurExone Biologic FCF Yield % Historical Data
* Premium members only.
The historical data trend for NurExone Biologic's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J90 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, NurExone Biologic's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NurExone Biologic FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NurExone Biologic's FCF Yield % distribution charts can be found below:
* The bar in red indicates where NurExone Biologic's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NurExone Biologic (FRA:J90) has a FCF Yield % of -13.03 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NurExone Biologic and its competitors. According to the industry distribution chart, NurExone Biologic ranks #803 out of 1415 companies in the Biotechnology industry, placing it in the top 56.7%.
Is NurExone Biologic's FCF Yield % too high?
NurExone Biologic's current FCF Yield % is -13.03. Based on the distribution chart, NurExone Biologic ranks #803 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NurExone Biologic has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #803 out of 1415 companies for FCF Yield %. This places NurExone Biologic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current FCF Yield % is -13.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current FCF Yield % of -13.03. The current FCF Yield % is -13.03. NurExone Biologic's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current FCF Yield % is -13.03 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
36GF Score
Get the complete analysis for FRA:J90
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J90 has been successfully added to your 
